Although Gilead’s recent quarterly results were worse than expected one strong ray of light was remdesivir thanks to the fact that the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) on May 1, 2020 for use against COVID-19. This was made possible based on an “adaptive trial” https://www.trialsitenews.com/remdesi… where the National Institute of Allergy and Infectious Diseases (NIAID) allowed an unprecedented change in trial endpoint leading to the FDA action. After the trial Dr. Fauci declared a “new standard of care” while also noting it was no “knock out drug.” What was the result? That Gilead forecasts sales totals for 2020 to be between $23 billion and $25 billion up from the range of $21.8 billion to $22.2 billion; and importantly, star analyst Michael Yee with Jefferies reports that this implies up to $1 to $3 billion of remdesivir sales. TrialSite also surveys alternative therapies under investigation targeting COVID-19 other than vaccines. As it turns out there is a lot more going on than many in nations such as the United States are aware, as the major media are careful about what investigational therapies get airtime.